Health Economics›Gallbladder cancer›Metastatic or unresectable disease all lines of therapy

Metastatic or unresectable disease all lines of therapy

Gallbladder cancer · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #01	—	R 132 655	28d	~2.2 mo	~9.4 mo	~2	~R 265 310 PFS proxy · indirect	11
GEMOX-B Variant #01	—	R 44 038	28d	—	—	~2	~R 88 077 indirect	—
Cisplatin and Gemcitabine (GC) and nab-Paclitaxel Variant #01	—	R 35 725	21d	~11.8 mo	—	~2	~R 71 450 PFS proxy · indirect	—
Erlotinib and Bevacizumab Variant #01	—	R 26 036	28d	~16.4 mo	~49.1 mo	~52	~R 1 353 852 PFS proxy · indirect	7
Gemcitabine and Mitomycin Variant #01	—	R 8 504	28d	—	—	~2	~R 17 008 indirect	—
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	8.3 mo	6	R 23 595 PFS proxy	1
FULV and Gemcitabine Variant #02	—	R 3 787	21d	—	—	~2	~R 7 575 indirect	—
Gemcitabine and S-1 Variant #01 Partial	—	R 3 344	21d	—	~26.1 mo	~2	~R 6 688 PFS proxy · indirect	2
GemOx Variant #01	—	R 2 937	14d	—	9.3 mo	7	R 20 560 PFS proxy	2
FELV Variant #01	—	R 2 934	21d	—	~12.0 mo	~2	~R 5 867 PFS proxy · indirect	—
Capecitabine and Mitomycin Variant #01	—	R 2 854	28d	—	—	~2	~R 5 708 indirect	—
CAPIRI Variant #05	—	R 2 849	21d	~5.9 mo	~16.8 mo	~9	~R 25 642 PFS proxy · indirect	2
Irinotecan monotherapy Variant #01	—	R 2 716	42d	~2.3 mo	~8.5 mo	~11	~R 29 874 PFS proxy · indirect	16
CapeOx Variant #01	—	R 2 620	21d	~6.7 mo	~12.2 mo	~6	~R 15 719 PFS proxy · indirect	20
ECF Variant #01	—	R 2 442	21d	—	~9.4 mo	~9	~R 21 982 PFS proxy · indirect	4
Gemcitabine, Cisplatin, S-1 Variant #01 Partial	—	R 1 819	14d	—	~13.5 mo	~2	~R 3 638 PFS proxy · indirect	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~4.7 mo	~6.8 mo	~7	~R 11 705 PFS proxy · indirect	31
Capecitabine monotherapy Variant #01	—	R 1 039	21d	~5.7 mo	~7.5 mo	~2	~R 2 077 PFS proxy · indirect	11
Best supportive care Partial	—	—	—	~1.7 mo	~4.3 mo	—	—	14

19 of 19 regimens shown